File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Development of novel osteoarthritis therapy by targeting AMPK-β-catenin-Runx2 signaling

TitleDevelopment of novel osteoarthritis therapy by targeting AMPK-β-catenin-Runx2 signaling
Authors
Zeng, DaofuUmar, MuhammadZhu, ZhenglinPan, HaoboLu, William WXiao, GuozhiChen, YanTong, LipingChen, Di
KeywordsAMPK
Osteoarthritis
Runx2
Signaling pathway
β-catenin
Issue Date1-Jan-2025
PublisherChongqing Medical University
Citation
Genes & Diseases, 2025, v. 12, n. 1 How to Cite?
DOI: http://dx.doi.org/10.1016/j.gendis.2024.101247
Abstract

Osteoarthritis (OA) is a debilitating chronic joint disease affecting large populations of patients, especially the elderly. The pathological mechanisms of OA are currently unknown. Multiple risk factors are involved in OA development. Among these risk factors, alterations of mechanical loading in the joint leading to changes in biological signaling pathways have been known as a key event in OA development. The importance of AMPK-β-catenin-Runx2 signaling in the initiation and progression of OA has been recognized in recent years. In this review, we discuss the recent progress in understanding the role of this signaling pathway and the underlying interaction mechanisms during OA development. We also discuss the drug development aiming to target this signaling pathway for OA treatment.


Persistent Identifierhttp://hdl.handle.net/10722/351329
ISSN
2352-4820
2023 Impact Factor: 6.9
2023 SCImago Journal Rankings: 1.446

 

DC FieldValueLanguage
dc.contributor.authorZeng, Daofu-
dc.contributor.authorUmar, Muhammad-
dc.contributor.authorZhu, Zhenglin-
dc.contributor.authorPan, Haobo-
dc.contributor.authorLu, William W-
dc.contributor.authorXiao, Guozhi-
dc.contributor.authorChen, Yan-
dc.contributor.authorTong, Liping-
dc.contributor.authorChen, Di-
dc.date.accessioned2024-11-20T00:38:33Z-
dc.date.available2024-11-20T00:38:33Z-
dc.date.issued2025-01-01-
dc.identifier.citationGenes & Diseases, 2025, v. 12, n. 1-
dc.identifier.issn2352-4820-
dc.identifier.urihttp://hdl.handle.net/10722/351329-
dc.description.abstract<p>Osteoarthritis (OA) is a debilitating chronic joint disease affecting large populations of patients, especially the elderly. The pathological mechanisms of OA are currently unknown. Multiple risk factors are involved in OA development. Among these risk factors, alterations of mechanical loading in the joint leading to changes in biological signaling pathways have been known as a key event in OA development. The importance of AMPK-β-catenin-Runx2 signaling in the initiation and progression of OA has been recognized in recent years. In this review, we discuss the recent progress in understanding the role of this signaling pathway and the underlying interaction mechanisms during OA development. We also discuss the drug development aiming to target this signaling pathway for OA treatment.</p>-
dc.languageeng-
dc.publisherChongqing Medical University-
dc.relation.ispartofGenes & Diseases-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAMPK-
dc.subjectOsteoarthritis-
dc.subjectRunx2-
dc.subjectSignaling pathway-
dc.subjectβ-catenin-
dc.titleDevelopment of novel osteoarthritis therapy by targeting AMPK-β-catenin-Runx2 signaling-
dc.typeArticle-
dc.identifier.doi10.1016/j.gendis.2024.101247-
dc.identifier.scopuseid_2-s2.0-85207749725-
dc.identifier.volume12-
dc.identifier.issue1-
dc.identifier.eissn2352-3042-
dc.identifier.issnl2352-3042-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats